AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for ...

Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections Inspira announced its bio-electronic ...

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

A series of reports released today by the European Centre for Disease Prevention and Control (ECDC) show sexually transmitted ...

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

Addresses the significant threat of antimicrobial resistance.

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

AbbVie announced that the US Food and Drug Administration (FDA) has approved Emblaveo (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/ß-lactamase inhibitor ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...